Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Marimed (MRMD) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Marimed (MRMD) over the last 11 years, with Q3 2025 value amounting to $382000.0.

  • Marimed's Share-based Compensation rose 3642.86% to $382000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year increase of 7719.48%. This contributed to the annual value of $1.0 million for FY2024, which is 294.12% up from last year.
  • As of Q3 2025, Marimed's Share-based Compensation stood at $382000.0, which was up 3642.86% from $549000.0 recorded in Q2 2025.
  • In the past 5 years, Marimed's Share-based Compensation ranged from a high of $5.6 million in Q3 2021 and a low of -$58000.0 during Q4 2022
  • Moreover, its 5-year median value for Share-based Compensation was $297000.0 (2023), whereas its average is $981470.6.
  • Within the past 5 years, the most significant YoY rise in Marimed's Share-based Compensation was 47758.62% (2023), while the steepest drop was 9158.24% (2023).
  • Over the past 5 years, Marimed's Share-based Compensation (Quarter) stood at $5.6 million in 2021, then plummeted by 101.04% to -$58000.0 in 2022, then surged by 477.59% to $219000.0 in 2023, then increased by 26.94% to $278000.0 in 2024, then skyrocketed by 37.41% to $382000.0 in 2025.
  • Its last three reported values are $382000.0 in Q3 2025, $549000.0 for Q2 2025, and $547000.0 during Q1 2025.